Range of mean changes from baseline in A1C in clinical studies of 24–52 weeks’ duration reported in prescribing information for five GLP-1 receptor agonists.

Slides:

Advertisements

Similar presentations

5S CLÍNICA MÉDICA (MH) 306 A. 5S CLÍNICA MÉDICA (MH) 306 B.

Advertisements

Insulin therapy.

Diabetes in the 21 st Century 2010 Update. American Diabetes Association 2010 Guidelines – Diagnostic Criteria A1C > or = 6.5% is included as diagnostic.

Consider this Combo: GLP-1 Receptor Agonists and Basal Insulin Matt Heinsen, PharmD PGY2 Pharmacotherapy Resident Butler University & Community Health.

Diabetes Update Part 2 of 3 Division of Endocrinology

GLP-1 Effectiveness, Mechanisms of Action and Potential Part 2.

Pathophysiology in the Treatment of Type 2 Diabetes Newer Agents Part 4 of 5.

New Insulin Formulations Guillermo Umpierrez, MD, FACP, FACE Professor of Medicine Emory University School of Medicine Part 1.

GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 3.

GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 4.

Supported by Virtual Poster Hall: Summary Slides Professor Stephan Matthaei Tuesday, September 15 th This Virtual Poster Hall session explores the relationship.

1 INTRODUCTION Nearly 25% of diabetes patients use insulin Many practitioners: –Are uncomfortable with insulin dosing –Base dosing decisions on empiric.

Small concise points on Insulin

2012 ADA Clinical Practice Guidelines Therapies for DM- Type 2

Copyright © 2015 by the American Osteopathic Association.

Basics of New PHASE Reporting

From: Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 DiabetesA Systematic Review and Meta-analysis Ann Intern Med.

Cycloset®A Dopamine Receptor Agonist Cycloset® -Bromocriptine: Safety Trial: Post Hoc Analysis of Cumulative Percent MACE Endpoint Bromocriptine (Parlodel)

Canagliflozin: Real World Experience

MK-0431 P051 PDT APPROVED 4/10/09 11/13/2018 2:49 PM

Updates on Emerging GLP-1 Receptor Agonists

Change (with 95% CI) in outcomes by duration of type 2 diabetes

Patient Case Discussions in T2D: What Intensification Plan Is Best?

Program Goals. Consulting the Experts: Prandial Insulin or a GLP-1 Receptor Agonist as Add-On to Basal Insulin.

Nilotinib 300 mg bid Nilotinib 400 mg bid Imatinib 400 mg qd n Median

Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1.

Clinical Application of New CV Outcomes Data

GLP-1 Receptor Agonists: How Early Is Appropriate?

Options for Combination Therapy in Type 2 Diabetes: Comparison of the ADA/EASD Position Statement and AACE/ACE Algorithm Timothy Bailey, MD The American.

Rate of provision of PCC

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

2008 FDA Guidance. Working as a Team for Cardiovascular Risk Reduction in Patients With T2D.

Summary of DURATION development program select efficacy results: absolute difference in change in A1C, body weight, systolic blood pressure, and LDL cholesterol.

Antihyperglycemic therapy in type 2 diabetes: general recommendations

Plasma active glucagon-like peptide-1 (GLP-1) response in patients with type 2 diabetes during the liquid high-fat meal test at baseline, 12 weeks and.

Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.

Average patient profile in terms of (A) previous therapy drug class and (B) complexity of previous regimen. Average patient profile in terms of (A) previous.

Impact of U-100 RHI administered with V-Go at OV1 (3 months after initiation) and OV2 (6 months after initiation) (n = 11) at 3 months (P = 0.32) and at.

Changes in A1C (A), body weight (B), and systolic blood pressure (C) with canagliflozin in combination with incretin-based therapies. *In the dose-advancement.

Trends in the relative contribution of each second-line diabetes medication class, by quarter, as a percent of all second-line prescribing, 2011–2015.

Change in HbA1c and weight compared with baseline variables for the liraglutide group and the placebo group. Change in HbA1c and weight compared with baseline.

(A) Correlation between change in HbA1c and change in weight from baseline to week 24 in the liraglutide group. (A) Correlation between change in HbA1c.

Kaplan-Meier plot of incident CVD according to the treatment group over a 4-year period following intensification of diabetes therapy. Kaplan-Meier plot.

Deep Dive: Examining Emerging GLP-1 RAs From a Clinical Perspective

Predicted and observed BMI levels using doubly robust estimation adjusting for either a comprehensive set of confounders (left panel) or a set of confounders.

Emerging Combination Injectable Therapy A New Era in Diabetes Care

ADA/EASD general recommendations for type 2 diabetes management (1).

Results of sensitivity analyses.

Change in %A1C over 5 years in response to 12-week intensive lifestyle intervention used in a real-world clinical practice. Change in %A1C over 5 years.

Range of mean changes from baseline in body weight in clinical studies of 24–52 weeks’ duration reported in prescribing information for five GLP-1 receptor.

INSULINS Dr.R.Sajjad december INSULINS Dr.R.Sajjad december 2018.

IGlarLixi SoloSTAR pen device and dose delivery of insulin glargine (units) and lixisenatide (µg) ranging from 15 units insulin glargine/5 µg lixisenatide.

Changes (mean +SEM) in glucose, insulin, glucagon-like peptide (GLP)-1 and ghrelin from the baseline values after administration of placebo (broken lines.

Comparative monthly and annual cost savings with RHI administered with V-Go. Comparative monthly and annual cost savings with RHI administered with V-Go.

GLP-1 and gastrin combination therapy restores normoglycemia in NOD mice. GLP-1 and gastrin combination therapy restores normoglycemia in NOD mice. Beginning.

GLP-1 and gastrin combination therapy increases pancreatic insulin content (A) and β-cell mass (B) in NOD mice. GLP-1 and gastrin combination therapy increases.

Multilevel Intervention Most scientific proof about developing health and health patronage.

Comorbid conditions and concomitant medications.

ORs of receiving metformin for outcome measures, including age, number of comorbidities, provider age, A1C level, history of CHF, and use of medications,

Glycemic control and body weight over 52 weeks.

ADA type 2 diabetes glycemic control algorithm, reproduced with permission from ref. 4. *Usually a basal insulin (neutral protamine Hagedorn, glargine,

Clinical responses to therapy from baseline to week 24 and end point with last observation carried forward (LOCF). Clinical responses to therapy from baseline.

Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.

Plasma glucose (A), serum insulin (B), serum C peptide (C) and plasma GLP-1 level (D) during the 2-hour OGTT among subjects with normal glucose tolerance.

A1C at baseline, 16 weeks, and 32 weeks according to study group in all participants (A), adult participants (B), and adolescent participants (C) who returned.

Antihyperglycemic therapy in adults with type 2 diabetes

Guideline approach to drug therapy in newly diagnosed type 2 diabetic patients not at target. Guideline approach to drug therapy in newly diagnosed type.

Fig. 1. Antihyperglycemic therapy algorithm for adult patients with type 2 diabetes mellitus (T2DM). The algorithm stratifies the choice of medications.

Baseline characteristics of people who inject drugs enrolled in the Montreal Hepatitis C Cohort (2004–2017), by prescribed dosage of opioid agonist treatment,

Time course of daily basal and mealtime insulin dose (A), glycated hemoglobin (B), laboratory-measured clinic FPG (C), prebreakfast SMPG (D), SMPG profiles.

Presentation transcript:

Range of mean changes from baseline in A1C in clinical studies of 24–52 weeks’ duration reported in prescribing information for five GLP-1 receptor agonists (13–18). Range of mean changes from baseline in A1C in clinical studies of 24–52 weeks’ duration reported in prescribing information for five GLP-1 receptor agonists (13–18). Each square represents the finding from one study. Drugs were tested as monotherapy or in combination with oral medications except as noted. *Finding reported as comparator in clinical study in another drug’s prescribing information. †Finding for drug in combination with insulin. QD, once daily. Deborah Hinnen Diabetes Spectr 2017;30:202-210 ©2017 by American Diabetes Association